Everolimus Tablet
Product Images NDC 0093-7769

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 0093-7769). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Images 1)

FDA Label Image

2 (Images 2)

FDA Label Image

1 (Images 3)

This is a summary of statistical analysis of a study related to cancer treatment with a drug called Everolimus compared with a placebo. The Hazard Ratio and Logrank p value are provided with the probability percentage. Additionally, Kaplan-Meier medians are reported for both treatment groups. It also mentions the censoring times for both the groups at week 4.*

FDA Label Image

1 (Images 4)

This appears to be a graph or table showing the probability of an event occurring over time for two different treatments, Everolimus + BSC and Placebo + BSC. The table also shows the number of patients at risk at each time point. The exact event being measured and the context of the data are not clear.*

FDA Label Image

1 (Images 5)

This appears to be a statistical output from a study or experiment involving two groups (Everolimus and Placebo). The table shows probability percentages and censoring times, as well as a hazard ratio and confidence interval with a significant p-value. Additionally, there are Kaplan-Meier medians for the two groups, indicating a significant difference in survival time between the two groups.*

FDA Label Image

2.5mg (Images 6)

FDA Label Image

5mg (Images 7)

FDA Label Image

7.5 mg (Images 8)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.